News

Sarepta Therapeutics laying off 80 employees in Ohio
Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...
MarketWatch3y
Sarepta stock plunges after FDA puts study on hold
Sarepta Therapeutics Inc. shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration.
Nasdaq4y
Is Sarepta Stock Worth Buying After the 50% Plunge? Analyst ... - Nasdaq
The treatment uses Sarepta’s peptide phosphorodiamidate morpholino oligomer (PPMO) technology.“With the stock trading near floor value of SRPT's exon-skipper base business,” Schwartz summed ...
Investing1mon
Sarepta stock plunges 42% after second fatal liver failure case
Sarepta stock plunges 42% after second fatal liver failure case ...
The Business Journals1mon
Sarepta stock plunges after second Duchenne patient death
A second Duchenne patient being treated with Sarepta's gene therapy has died, sending the biotech's stock plummeting. Thursday, July 31, 2025 Biotech's Future - Innovation, AI and our Competitive ...
MarketWatch4y
Sarepta stock plunges more than 50% after mixed results ... - MarketWatch
Sarepta stock plunges more than 50% after mixed results from drug study Pharmaceutical company says study of drug aimed at a form of muscular dystrophy showed strong early results, but longer-term ...
Forbes4y
After A 50% Fall Sarepta Therapeutics Stock Now Looks Attractive - Forbes
Sarepta Therapeutics stock, ... This news last week led to a 50% plunge from levels of close to $170 in early January to $82 in a single trading session.